Covid-19 | Page 27 of 100 | Links Medicus Content Curation & Alerts in Medicine

Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.

24 Jan, 2022 | 08:52h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid-19 Advisory for Ontario

Commentary on Twitter (thread – click for more)

https://twitter.com/ASPphysician/status/1484874519252721664

WHO Technical Brief: Enhancing response to Omicron SARS-CoV-2 variant.

24 Jan, 2022 | 08:36h | UTC

Enhancing response to Omicron SARS-CoV-2 variant – World Health Organization

A guide to immunotherapy for COVID-19.

24 Jan, 2022 | 08:29h | UTC

A guide to immunotherapy for COVID-19 – Nature Medicine

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

24 Jan, 2022 | 08:28h | UTC

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity – Cell

Commentary on Twitter:

A simple😉one-page summary of everything you need to know about Covid hallmarks of severity in the blood, how it differs from flu, sepsis, and much morehttps://t.co/s81Qb2SXmu @CellCellPress @KnightGenetics
(actually quite a rich resource @UniofOxford) pic.twitter.com/bk0AxwLItn

— Eric Topol (@EricTopol) January 22, 2022

Flying in the COVID-19 era: Science-based risk assessments and mitigation strategies on the ground and in the air.

24 Jan, 2022 | 08:32h | UTC

Flying in the COVID-19 Era: Science-based Risk Assessments and Mitigation Strategies on the Ground and in the Air – National Academies of Sciences, Engineering, and Medicine (free registration required)

SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses.

24 Jan, 2022 | 08:26h | UTC

SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses – Cell

News Release: Breakthrough infections spur strong antibody responses – University of Washington School of Medicine

Opinion: COVID-19 will continue but the end of the pandemic is near.

21 Jan, 2022 | 10:16h | UTC

COVID-19 will continue but the end of the pandemic is near – The Lancet

Commentary on Twitter

.@IHME_UW's Chris Murray predicting the end of the pandemic is nigh
"More than 50% of the world will have been infected with omicron …[by] the end of March, 2022"
"After the omicron wave, COVID-19 will return but the pandemic will not."https://t.co/9NSw8lZuUe @TheLancet

— Eric Topol (@EricTopol) January 20, 2022

RCT: Immunogenicity and reactogenicity of different vaccine boosters after a first J&J vaccine.

21 Jan, 2022 | 10:12h | UTC

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming – New England Journal of Medicine

Commentary on Twitter

Trial examined effects of boosting with one of the three approved #COVI19 vaccines — AD26.COV2.S, mRNA-1273, or BNT162b2 — 3 mos after the primary vaccination. All increased neutralizing-antibody levels & T-cell responses; mRNA vaccines were higher. https://t.co/qkpQFvNliJ pic.twitter.com/MUfa1OEsLP

— NEJM (@NEJM) January 19, 2022

Opinion: Now that science has defanged Covid, it’s time to get on with our lives.

21 Jan, 2022 | 10:14h | UTC

Now that science has defanged Covid, it’s time to get on with our lives – The Guardian

Perspective: Nervous system consequences of COVID-19.

21 Jan, 2022 | 10:10h | UTC

Nervous system consequences of COVID-19 – Science

Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

Review: Counting the neurological cost of COVID-19.

Infection with Covid-19 carries a much higher risk of developing neurological complications than Covid-19 vaccines.

M-A: Frequency of Neurologic Manifestations in COVID-19 – up to one-third of patients (89% hospitalized) experienced at least one neurological manifestation.

Neurological Effects of COVID-19 in Children.

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

Short review: Neurological complications of COVID-19.

2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.

M-A: Encephalitis as Neurological Complication of COVID‐19.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions Eight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

[Preprint] Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies – up to one-third of COVID-19 patients analyzed in this review, 89% of whom were hospitalized, experienced at least one neurological manifestation

Commentary on Twitter

A new #SciencePerspective discusses the neurological symptoms that accompany #COVID19 and the possible mechanisms that cause them. Read more: https://t.co/WKZpnWlbNc pic.twitter.com/U4ohecaVQd

— Science Magazine (@ScienceMagazine) January 20, 2022

Review: Postdischarge Evaluation for Individuals Hospitalized with COVID-19.

21 Jan, 2022 | 10:08h | UTC

Postdischarge Evaluation for Individuals Hospitalized with COVID-19 – Southern Medical Journal

Europe considers new COVID-19 strategy: Accepting the virus.

21 Jan, 2022 | 10:13h | UTC

Europe considers new COVID-19 strategy: Accepting the virus – Associated Press

[Preprint] COVID infection severity in children under 5 years old before and after Omicron emergence in the US.

21 Jan, 2022 | 10:04h | UTC

COVID infection severity in children under 5 years old before and after Omicron emergence in the US – medRxiv

Commentary: SARS-CoV-2 Omicron infections milder in children compared to Delta – News Medical

Editorial | Covid-19 vaccines and treatments: we must have raw data, now.

21 Jan, 2022 | 10:00h | UTC

Covid-19 vaccines and treatments: we must have raw data, now – The BMJ

News Release: Editors call for covid-19 vaccine and treatment data to be available for public scrutiny – The BMJ

WHO’s Emergencies expert group re-asserts stance against covid ‘vaccine passports’ for international travel.

21 Jan, 2022 | 10:02h | UTC

WHO’s Emergencies Expert Group Re-Asserts Stance Against COVID ‘Vaccine Passports’ for International Travel – Health Policy Watch

Editorial | Long covid in children and adolescents – “Risk appears low, but many questions remain”.

21 Jan, 2022 | 09:58h | UTC

Long covid in children and adolescents – The BMJ

M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.

Review: Long COVID symptoms in children rarely persist beyond three months.

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

Commentary on Twitter

"As SARS-CoV-2 remains predominantly a mild infection in the paediatric population, the incidence of long covid is a critical factor in the risk-benefit equation for policy and parental decisions on covid-19 vaccines for children," says Editorialhttps://t.co/POidCyS2RZ

— The BMJ (@bmj_latest) January 20, 2022

Booster longevity: Data reveals how long a third shot protects.

20 Jan, 2022 | 09:33h | UTC

Booster longevity: Data reveals how long a third shot protects – NPR

Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.

20 Jan, 2022 | 09:30h | UTC

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine

Commentary on Twitter

In two matched retrospective cohort studies comparing BNT162b2 and mRNA-1273, both were highly effective at preventing hospitalization & death. Breakthrough infections were lower among those who received mRNA-1273 than those who received BNT162b2. https://t.co/wgkrzfLNHz pic.twitter.com/E8hXIDFqWW

— NEJM (@NEJM) January 19, 2022